Literature DB >> 17388952

The immunopathology of multiple sclerosis: an overview.

Hans Lassmann1, Wolfgang Brück, Claudia F Lucchinetti.   

Abstract

Multiple sclerosis (MS) is traditionally seen as an inflammatory demyelinating disease, characterized by the formation of focal demyelinated plaques in the white matter of the central nervous system. In this review we describe recent evidence that the spectrum of MS pathology is much broader. This includes demyelination in the cortex and deep gray matter nuclei, as well as diffuse injury of the normal-appearing white matter. The mechanisms responsible for the formation of focal lesions in different patients and in different stages of the disease as well as those involved in the induction of diffuse brain damage are complex and heterogeneous. This heterogeneity is reflected by different clinical manifestations of the disease, such as relapsing or progressive MS, and also explains at least in part the relation of MS to other inflammatory demyelinating diseases.

Entities:  

Mesh:

Year:  2007        PMID: 17388952     DOI: 10.1111/j.1750-3639.2007.00064.x

Source DB:  PubMed          Journal:  Brain Pathol        ISSN: 1015-6305            Impact factor:   6.508


  362 in total

1.  Integration of MicroRNA databases to study MicroRNAs associated with multiple sclerosis.

Authors:  Charlotte Angerstein; Michael Hecker; Brigitte Katrin Paap; Dirk Koczan; Madhan Thamilarasan; Hans-Jürgen Thiesen; Uwe Klaus Zettl
Journal:  Mol Neurobiol       Date:  2012-05-02       Impact factor: 5.590

Review 2.  Multiple sclerosis.

Authors:  Alyssa Nylander; David A Hafler
Journal:  J Clin Invest       Date:  2012-04-02       Impact factor: 14.808

Review 3.  CCSVI and MS: a statement from the European Society of neurosonology and cerebral hemodynamics.

Authors:  Claudio Baracchini; José M Valdueza; Massimo Del Sette; Galina Baltgaile; Eva Bartels; Natan M Bornstein; Juergen Klingelhoefer; Carlos Molina; Kurt Niederkorn; Mario Siebler; Matthias Sturzenegger; Bernd E Ringelstein; David Russell; Laszlo Csiba
Journal:  J Neurol       Date:  2012-05-31       Impact factor: 4.849

4.  ["Chronic cerebrospinal venous insufficiency" and multiple sclerosis: critical analysis and first observation in an unselected cohort of MS patients].

Authors:  C Krogias; A Schröder; H Wiendl; R Hohlfeld; R Gold
Journal:  Nervenarzt       Date:  2010-06       Impact factor: 1.214

5.  Practical considerations on the use of rituximab in autoimmune neurological disorders.

Authors:  Mixalis L Kosmidis; Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2010-03       Impact factor: 6.570

6.  Innovative monoclonal antibody therapies in multiple sclerosis.

Authors:  Ralf A Linker; Bernd C Kieseier
Journal:  Ther Adv Neurol Disord       Date:  2008-07       Impact factor: 6.570

7.  A multiparametric evaluation of regional brain damage in patients with primary progressive multiple sclerosis.

Authors:  Antonia Ceccarelli; Maria A Rocca; Paola Valsasina; Mariaemma Rodegher; Elisabetta Pagani; Andrea Falini; Giancarlo Comi; Massimo Filippi
Journal:  Hum Brain Mapp       Date:  2009-09       Impact factor: 5.038

Review 8.  First-line natalizumab in multiple sclerosis: rationale, patient selection, benefits and risks.

Authors:  Jacqueline Ann Nicholas; Michael Karl Racke; Jamie Imitola; Aaron Lee Boster
Journal:  Ther Adv Chronic Dis       Date:  2014-03       Impact factor: 5.091

Review 9.  Mechanisms of action of ACTH in the management of relapsing forms of multiple sclerosis.

Authors:  Regina Berkovich; Mark A Agius
Journal:  Ther Adv Neurol Disord       Date:  2014-03       Impact factor: 6.570

Review 10.  Melatonin and Multiple Sclerosis: From Plausible Neuropharmacological Mechanisms of Action to Experimental and Clinical Evidence.

Authors:  Mahshid Yeganeh Salehpour; Adriano Mollica; Saeideh Momtaz; Nima Sanadgol; Mohammad Hosein Farzaei
Journal:  Clin Drug Investig       Date:  2019-07       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.